Clinical Trials Logo
  1. Home
  2. Safety and Efficacy
  3. NCT04994210

Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

Safety and Efficacy Clinical Trial

Official title:
Safety and Efficacy of Sintilimab(S) in Combination With Histone Deacetylase Inhibitor (Chidamide, C) in Newly Diagnosed Extranodal Natural Killer Cell/T-cell Lymphoma(EN): A Single-arm, Multicenter Phase II Study(SCENT-2)

Clinical Trial Summary

ENKTL is a highly aggressive NHL with a higher incidence in Asia. L-asparaginase containing chemotherapy regimens are the standard first-line treatment with apparently toxicities. In 2020 ASH, the investigators reported Sintilimab(anti-PD-1 antibody) plus Chidamide(an oral subtype-selective HDACi) yielded effective antitumor activity, durable response in patients with relapsed or refractory ENKTL(SCENT trial. Abstracts 644). The investigators next conducted a exploratory study to investigated the safety and efficacy of Sintilimab plus Chidamide(SC) for patients with newly diagnosed ENKTL(SCENT-2 trial).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04994210
Study type Interventional
Source Sun Yat-sen University
Contact Nan-qiao Cai, Professor
Phone +86 020-84115962
Email sysunsfc@mail.sysu.edu.cn
Status Recruiting
Phase Phase 2
Start date October 4, 2021
Completion date August 31, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT05247957 - NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia N/A
Completed NCT04621123 - Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients Phase 2
Recruiting NCT05140616 - Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD Phase 1/Phase 2
Recruiting NCT05349552 - Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Completed NCT03820596 - Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL Phase 1/Phase 2
Not yet recruiting NCT05556889 - Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block N/A
Recruiting NCT04446806 - Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Phase 4
Not yet recruiting NCT06244537 - Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer N/A
Recruiting NCT03455972 - Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT Phase 1/Phase 2
Completed NCT04785170 - Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals N/A
Recruiting NCT04677452 - Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM Phase 1
Completed NCT01305044 - The HEALS Project - Health Education and Active Living for Surviving Seniors Phase 2
Active, not recruiting NCT04646590 - A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 Phase 3
Recruiting NCT05021276 - Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD Phase 4
Not yet recruiting NCT05008666 - Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH Phase 2
Recruiting NCT06066840 - Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement Phase 4
Active, not recruiting NCT04852068 - A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells) Phase 3